Tradestie Institutional Equity Comparison Engine

MLTX vs WVE โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MLTX Overall Edge

MLTX Captures Institutional Edge (3โ€“0 Pillars ยท 4โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, MLTX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus WVE at N/M Forward P/E and -320.9% operating margin (+73.0% YoY). In options structure, MLTX sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro) against WVE sits in BREAKDOWN (62nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
MLTX N/M vs WVE N/M Fwd P/E
Growth & Margin Winner MLTX
Op Margin 0.0% vs -320.9% ยท YoY +0.0% vs +73.0%
Momentum & Technical Winner MLTX
1Y -5.7% vs -56.8% ยท 52W Pos 17% vs 0%
Options & Structure Winner MLTX
BREAKDOWN (7th %ile IV) vs BREAKDOWN (62nd %ile IV)
MLTX NASDAQ
MoonLake Immunotherapeutics Class A Ordinary Shares
Pharmaceutical Preparations
$11.85
-5.2% 1D
Market Cap $1.1B
1M Return +24.08%
1Y Return -5.65%
Forward P/E N/M
Unified AI Score
38.3 / 100 SELL
Tech 32.0 Fund 44.0 Flow 75.0 Mom 50.0
WVE NASDAQ
Wave Life Sciences Ltd. Ordinary Shares
Pharmaceutical Preparations
$2.89
-7.82% 1D
Market Cap $621.3M
1M Return -7.82%
1Y Return -56.75%
Forward P/E N/M
Unified AI Score
41.5 / 100 SELL
Tech 21.0 Fund 46.0 Flow 68.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MLTX -5.65% WVE -56.75% Spread: +51.1 pp (MLTX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MLTX TTM Op. Margin: 0.0% WVE TTM Op. Margin: -320.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MLTX vs WVE. Trailing 12-month operating profitability (MLTX 0.0% vs WVE -320.9%) and valuation multiples (MLTX N/M vs WVE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MLTX (4) vs WVE (4)
Institutional Metric MLTX WVE Criterion Row Winner
Market Capitalization Scale $1.1B $621.3M Larger Scale MLTX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +73.0% Higher Growth WVE
Operating Margin (TTM) Profitability 0.0% -320.9% Higher Margin MLTX
Net Profit Margin Profitability 0.0% -296.9% Higher Margin MLTX
Return on Equity (ROE) Capital Efficiency -81.5% -78.8% Higher ROE WVE
52-Week Range Position Momentum 17% ($9โ€“$23) 0% ($3โ€“$21) Stronger Trend MLTX
Beta / 30D Volatility Risk Regime 1.61ฮฒ ยท 90% Vol 1.94ฮฒ ยท 76% Vol Lower Realized Risk WVE
Unified Institutional Score Composite Signal 38.3 / 100 (SELL) 41.5 / 100 (SELL) Higher Composite WVE

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MLTX vs WVE Buy Guide
MLTX BREAKDOWN
103d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 7th %ile
IV Regime Compressed (<25th %ile)
Live MLTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
WVE BREAKDOWN
149d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 62nd %ile
IV Regime Elevated (60thโ€“80th %ile)
Live WVE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MLTX nor WVE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.